

29.06.2020

16:30–16:55 Opening Ceremony

16:30 Welcome to the first EHF online congress
Z. Katsarava (Unna, Essen/DE), R. B. Lipton (Bronx/US)

16:35 Update on the idiopathic intracranial hypertension
A. Sinclair (Birmingham/GB)

17:00–18:10 Scientific Session 1 – Clinical Research

Chairs U. Reuter (Berlin/DE), N. Vandenbussche (Gent/BE)

17:00 Medication overuse headache in the era of CGRP
IL01 R. B. Lipton (Bronx/US)

17:20 Hypersensitivity to Calcitonin Gene-Related Peptide in Post-Traumatic Headache attributed to Mild Traumatic Brain Injury: A Randomized Clinical Trial.
AL02 H. Ashina, A. Iljazi, H. Al-Khazali, C. E. Christensen, F. M. Amin, M. Ashina, H. W. Schytz (Glostrup/DK)

17:35 A randomised, placebo controlled, double blind trial of the effect of the GLP-1 receptor agonist Exenatide on intracranial pressure in Idiopathic Intracranial Hypertension (IIH: Pressure Trial).
AL05 J. Mitchell, J. Walker, H. Lyons, K. Brock, V. Vijay, A. Yiangou, Z. Alimajstorovic, O. Grech, G. Tsermoulas, S. Mollan, A. Sinclair (Birmingham/GB)

17:40 Bridging the gap between cortical spreading depression and headache
IL02 R. Burstein (Boston/US)

18:20–18:50 Poster Session and Break – Poster of the Day

Chairs M. Braschinsky (Tartu/EE), J. Kruja (Tirana/AL), F. M. Amin (Copenhagen/DK)

18:20–18:50 Chronic Headache

P01 Possible effects, adverse and side-effects of Ketamine, a NMDA receptor antagonist in resistant chronic migraine- cohort observation 1994-2019- pilot data
M. Nicolodj, M. S. Pinnaro, A. Torrini, V. Sandoval, P. L. Del Bianco (Florence/IT), R. Conigliaro, F. Sicuteri (Torino, Florence/IT)

P02 Patient-identified most bothersome symptom in patients with chronic migraine: an analysis of PROMISE-2
R. B. Lipton (Bronx/US), D. W. Dodick (Phoenix/US), J. Ailani (Washington/US), P. Winner (Fort Lauderdale/US), N. A. Hindiyeh (Stanford/US), J. Hirman (Woodinville/US), S. Snapinn, L. Mehta, R. Cady (Bothell/US)

P03 ERENUMAB IN CHRONIC MIGRAINE: EFFICACY AND RESPONSE PREDICTORS FROM AN ITALIAN MULTICENTRIC OBSERVATIONAL STUDY.
R. Rao, F. Schiano di Cola, S. Caratozzolo (Brescia/IT), E. Venturelli (Bergamo/IT), U. Balducci, V. Sidoti (Chiari/IT), E. Pari, C. Costanzi (Crema/IT), A. di Summa, G. J. Sixt (Bozen/IT), E. D'Adda (Crema/IT), P. Liberini, A. Padovani (Brescia/IT)

P04 Exploring the boundaries between episodic and chronic migraine: Results from the CaMEO Study

R. B. Lipton (Bronx/US), M. L. Reed, K. M. Fanning (Chapel Hill/US), D. C. Buse (Bronx/US), P. J. Goadsby (London/GB), J. Olesen (Copenhagen/DK), D. W. Dodick (Phoenix/US), A. Manack Adams (Irvine/US)

- P05 Erenumab in highly refractory Chronic Migraine patients with Medication Overuse Headache: a single centre real-life study.
U. Pensato, V. Favoni, A. Pascazio, M. Benini, G. M. Asioli, E. Merli, C. Calabrò, P. Cortelli, G. Pierangeli, S. Cevoli (Bologna/IT)
- P06 Ketogenic diet in pediatric patients with chronic migraine
R. Moavero, D. Elia, L. Papetti, M. A. N. Ferilli, F. Ursitti, S. Tarantino, C. Dionisi Vici, F. Vigevano, M. Valeriani (Rome/IT)
- P07 Longitudinal evaluation of tolerability of Onabotulinumtoxin A in pediatric chronic migraine.
L. Papetti, C. Ruscitto, G. Sforza, F. Ursitti, M. A. N. Ferilli, R. Moavero, S. Tarantino, M. Valeriani (Rome/IT)
- P08 Erenumab in Refractory Chronic Migraine patients: Real-life results from an Italian tertiary Headache Center
V. Favoni, U. Pensato, A. Pascazio, M. Benini, G. M. Asioli, E. Merli, C. Calabrò, P. Cortelli, G. Pierangeli, S. Cevoli (Bologna/IT)
- P09 Sustained Clinical Benefits Following OnabotulinumtoxinA Treatment in Patients With Chronic Migraine: A Post Hoc Analysis of the Pooled PREEMPT Studies
D. W. Dodick (Phoenix/US), H.-C. Diener (Essen/DE), S. D. Silberstein (Philadelphia/US), L. Yedigarova (Irvine/US), R. B. Lipton (Bronx/US)
- P10 Does symptomatic treatment help children and adolescents with chronic migraine?
M. A. N. Ferilli, L. Papetti, F. Ursitti, R. Moavero, S. Tarantino, G. Sforza, F. Vigevano (Rome/IT), M. Valeriani (Rome/IT, Aalborg/DK)
- P11 Healthcare resource utilization and health-related quality of life in adult patients with chronic migraine: Results from the PREDICT study
G. Boudreau (Montreal/CA), I. Finkelstein (Toronto/CA), C. Graboski (Brentwood Bay/CA), M. Ong-Lam (Vancouver/CA), S. Christie (Ottawa/CA), K. Sommer (Marlow, Buckinghamshire/GB), M. Bhogal, G. Davidovic (Markham/CA), W. J. Becker (Calgary/CA)
- P12 CGRP plasma levels and peripheral expression of specific microRNAs in chronic migraine with medication-overuse: changes induced by detoxification
R. Greco, C. Demartini, A. M. Zanaboni, E. Tumelero, R. De Icco, G. Sances, M. Allena, C. Tassorelli (Pavia/IT)
- P13 The use of the Severity of Dependence Scale to the severity of analgesics dependence: An Italian study
S. Bottiroli, G. Sances, R. De Icco, M. Allena, E. Guaschino, C. Tassorelli (Pavia/IT)
- P14 Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study German population
K. Kollwe (Hannover/DE), C. Gaul (Königstein/DE), A. Gendolla (Essen/DE), K. Sommer (Marlow, Buckinghamshire/GB)
- P15 Migraine patients with and without medication overuse headache and dependency rate
P. Merbaum, G. Tabeeva (Moscow/RU)

- P16 Erenumab in chronic migraine patients with prior non-successful onabotulinumtoxinA therapy: a multicentre retrospective observational study
B. Raffaelli, R. Kalantzis, J. Mecklenburg, L. H. Overeem, L. Neeb (Berlin/DE), A. Gendolla (Essen/DE), U. Reuter (Berlin/DE)
- P17 Reduction of sleep fragmentation and of anxiety levels after withdrawal of acute painkilling drugs in medication overuse headache Valente M, Bevilacqua F, Garbo R, Pez S, Gigli GL Clinical Neurology, University of Udine, Udine, Italy
M. Valente, F. Bevilacqua, R. Garbo, S. Pez, G. L. Gigli (Udine/IT)
- P18 Efficacy of Fremanezumab in Patients With Episodic and Chronic Migraine And Inadequate Response to 2-4 Classes of Migraine Preventive Medication by Therapeutic Class With Inadequate Response Due to Lack of Efficacy: Results of the International, Multicenter Phase 3b FOCUS Study
L. Pazdera (Rychnov nad Kněžnou/CZ), J. M. Cohen, X. Ning, L. J. Krasenbaum, R. Yang, M. Seminerio (West Chester/US)
- P19 Early Efficacy of Fremanezumab in Patients With Episodic and Chronic Migraine and Inadequate Response to 2-4 Classes of Migraine Preventive Medications Due to Lack of Efficacy: Results of the International, Multicenter Phase 3b FOCUS Study
A. J. Starling (Scottsdale/US), V. Ramirez–Campos, R. Yang, J. M. Cohen (West Chester/US), M. Galic (Amsterdam/NL), X. Ning, K. Carr (West Chester/US), C. Treppendahl (Ridgeland/US)
- P20 Correlation between the tolerability to onabotulinumtoxinA administration and the presence of adverse events: A prospective cohort study.
Á. Sierra-Mencia, M. Gutierrez Sanchez, B. Martínez Rodriguez, D. Gil Contreras, Á. L. Guerrero Peral, B. Talavera de la Esperanza, D. García-Azorín (Valladolid/ES)
- P21 Early Efficacy of Fremanezumab in Episodic and Chronic Migraine in Patients Who Had "Failed" Preventive Medication: Lack of Previous Efficacy Based on Therapeutic Class Prior to the International, Multicenter Phase 3b FOCUS Study
J. Lewis Brandes (Nashville/US), J. M. Cohen, X. Ning, L. J. Krasenbaum, R. Yang, M. Seminerio (West Chester/US)
- P22 Safety of Fremanezumab in Patients With Episodic and Chronic Migraine and Inadequate Response to 2-4 Classes of Migraine Preventive Medication Due to Poor Tolerability: Results of the International, Multicenter Phase 3b FOCUS Study
S. J. Nahas (Philadelphia/US), J. M. Cohen, Y. Kessler, X. Ning, R. Yang, K. Carr (West Chester/US), D. Kudrow (Santa Monica/US)
- P23 Efficacy of Fremanezumab in Patients with Migraine and Documented Inadequate Response to 3 or 4 Migraine Preventive Medication Classes and Medication Overuse in the International, Multicenter, Randomized, Placebo-controlled FOCUS Study
L. Pazdera (Rychnov nad Kněžnou/CZ), X. Ning, V. Ramirez–Campos, R. Yang, K. Carr, J. M. Cohen (West Chester/US)
- P24 Efficacy of Fremanezumab in Subjects With Migraine and Prior Inadequate Response to Valproic Acid, Topiramate, or OnabotulinumtoxinA in the Open-label Period of the International, Multicenter, Randomized, Placebo-controlled FOCUS Study
A. J. Nagy (Las Vegas/US), X. Ning (West Chester/US), M. Galic (Amsterdam/NL), J. M. Cohen, R. Yang, M. Seminerio (West Chester/US), L. Mechtler (Buffalo/US)

- P25 Long-Term Efficacy of Fremanezumab in Patients With Episodic Migraine and Chronic Migraine Who Failed At Least One Prior Migraine Preventive Medication: Results From 6- and 12-Month Studies
C. Dougherty (Washington/US), X. Ning, J. M. Cohen, R. Yang, V. Ramirez–Campos, M. Seminerio (West Chester/US), S. D. Silberstein (Philadelphia/US)
- P26 Opioids use for acute migraine treatment and the risk of recurrent visit to the Emergency Department in a tertiary Hospital in Brazil
M. N. P. Souza, G. Kubota, A. P. D. S. Oliveira, L. S. Zambon, M. R. . Jordão, M. Calderaro (São Paulo/BR)
- P27 A Multicenter Cooperative REgistry for Load and Management of MEDicAtion OveruSE Headache
H.-K. Park (Goyang/KR), S.-J. Cho (Hwaseong/KR)
- P28 THE HIGHER THE HEADACHE FREQUENCY, THE BETTER THE RESPONSE TO ONABOTULINUMTOXINA IN PATIENTS WITH CHRONIC MIGRAINE
D. García-Azorín, M. Gutierrez Sanchez, Á. Sierra-Mencía, D. Gil Contreras, B. Martínez Rodriguez, Á. L. Guerrero Peral (Valladolid/ES)
- P29 The clinical utility of a pragmatic criterion for assessing the response of chronic migraine to preventive therapy and its predictors in a cohort of 403 patients.
A. Viganò (Milan/IT), E. Simoncelli, B. Petolicchio, I. Maestrini, M. Toscano, M. Puma (Rome/IT), R. De Sanctis (Pieve Emanuele/IT), M. Alessiani, V. Di Piero (Rome/IT)
- P30 Evaluation of anxiety –depressive disturbances and headache related disability in patients with chronic and episodic migraine.
C. Rustamova, M. Yakubova (Tashkent/UZ)
- P31 Frequent Severe Vertigo Abolished by the Onabotulinum toxin A therapy in Patient with Chronic Migraine: A Case Report
G. S. Kim, H.-K. Park (Goyang/KR)
- P32 Chronic Headache Prevalence and Helicobacter pylori Infection in Outpatients
N. Ninashvili, M. Shavdia, N. Chakvetadze, K. Tchaava, N. Gegeshidze (Tbilisi/GE)
- P33 NEUROSTIMULATION AS ONE OF THE MOST EFFECTIVE METHODS OF TREATMENT OF CHRONIC MIGRAINE
M. Kurnukhina, A. Gusev (St. Petersburg/RU)
- P34 SURGERY AS AN ALTERNATIVE AND EFFECTIVE METHOD OF TREATMENT CHRONIC MIGRAINE
A. Gusev, M. Kurnukhina (St. Petersburg/RU)
- P35 Effects of depression, anxiety and sleep disturbances on the quality of life in patients with episodic and chronic migraine
K. Abdurakhmonova, G. Rakhimbaeva (Tashkent/UZ)
- P36 Body mass index and its association with episodic and chronic migraine
K. Abdurakhmonova, G. Rakhimbaeva (Tashkent/UZ)
- P37 Factors of migraine chronization: data from a medical and social online survey
N. Kovalchuk (Moscow/RU)

- P38 Stress management efficacy in the treatment of chronic headache and comorbid immune disorders.
A. Prishchepa, A. Danilov (Moscow/RU)
- P39 Analysis of the Efficacy and Safety of 210 refractory migraine patients treated with erenumab in a personalized managed access program in Spain
R. Belvis (Barcelona/ES), M. Sanchez del Rio (Madrid/ES), P. Irimia (Pamplona/ES), A. Alpuente (Barcelona/ES), C. González Oria (Sevilla/ES), A. Cano (Barcelona/ES), F. J. Viguera Romero (Sevilla/ES), B. Sanchez (Zaragoza/ES), F. J. Molina (Palma de Mallorca/ES), I. Beltran (Alicante/ES), A. Oterino (Santander/ES), E. Cuadrado-Godía (Barcelona/ES), A. Gómez Camello (Granada/ES), M. Alberte-Woodward (Lugo/ES), C. Jurado Cobo (Córdoba/ES), B. Oms (Barcelona/ES), D. Ezpeleta, J. Diaz de Teran (Madrid/ES), N. Morollon (Barcelona/ES), G. Latorre (Madrid/ES), R. Leira (Santiago de Compostela/ES), S. Santos-Lasaosa (Zaragoza/ES)
- P40 Epidemiology of headache in a Mexican Tertiary-care center
R. Garcia, R. Carrera, J. Hernandez (Mexico City/MX)

18:20–18:50 Clinical Research

- P41 The Impact Of Obesity On Migraine Clinical Presentation And Treatment Response Among A Sample Of Egyptian Patients
M. M. Hamdy, N. M. Nasreldine, A. Fawzy, E. Hamdy (Alexandria/EG)
- P42 The Impact Of Sociodemographic Characteristics On Migraine Burden In Egypt
M. M. Hamdy, N. M. Nasreldine, A. Fawzy, E. Hamdy (Alexandria/EG)
- P43 The Relationship between Pain Catastrophizing Level, Extreme Sensory Processing Patterns and Headache Severity among Adolescents with Migraine
J. Genizi (Haifa/IL), A. Halevy (Petach Tikva/IL), M. Schertz (Petach Tikva, Haifa/IL), K. Osman, N. Assaf, I. Segal, I. Srugo, A. Kessel, B. Engel-Yeger (Haifa/IL)
- P44 Psychoemotional distress in parents of patients with Childhood Autism: a cohort study.
T. Voloshyn (Truskavets/UA)
- P45 The impact of headaches and related factors on mothers raising young children
H. Kawasaki, M. Kawasaki, S. Yamasaki, M. Nishiyama, P. D'Angelo (Hiroshima/JP), T. Iki (Awaji/JP)
- P46 Poverty leading to headach
M. J. Mwambu (Kampala/UG)
- P47 Effects of Headache on Depressive Symptoms in Elderly Population: The Case of Turkey
N. Yagci, S. Simsek (Denizli/TR)
- P48 Recurrent Headache in Indian Adolescents in New Delhi public school.
P. Kumar, V. Sharma (New Delhi/IN)
- P49 Migraine knowledge and awareness among Nepalese Population: still in infancy
R. Ojha, N. Guragain, R. Karn (Kathmandu/NP)
- P50 INFLUENCE OF MIGRAINE AND BAD SELF-RATED HEALTH ON PUBLIC HEALTH AND INTEGRATIVE MEDICINE SERVICES USE IN SLOVENIA
M. Zaletel, M. Popit, L. Kragelj-Zaletel, B. Žvan (Ljubljana/SI)

- P51 The prevalence of migraine among patients at primary care clinic and specialized pain clinic
E. Malenkova, L. Medvedeva, O. Zagorulko, G. Shevtsova (Moscow/RU)
- P52 Migraine-related disability and co-morbid depression among migraineurs in Ethiopia: a cross-sectional study
B. Ayele, Y. Yifru (Addis Ababa/ET)
- P53 Economic impact of migraine in employed adult patients with migraine from the United States: Results from the Medical Expenditure Panel Survey (MEPS)
S. Joshi (New York/US), J. H. Ford, W. Ye, J. S. Andrews (Indianapolis/US), R. Bhandari (Bangalore/IN), R. Okonkwo, D. Nelson (Indianapolis/US)
- P54 FACTORS INFLUENCING THE COURSE OF CERVICOGENIC HEAD PAIN, EFFECTIVENESS OF MANUAL THERAPY
A. Borisenko, S. Likhachev, V. Vashchylin (Minsk/BY)
- P55 The importance of considering the patient's and treating physician's view to generate comprehensive und unbiased real-world evidence data
K. Schuh (Nuremberg/DE), C. Gaul (Königstein/DE), A. Straube (Munich/DE), P. Stude (Bochum/DE), H. Israel-Willner (Berlin/DE), M. Koch (Nuremberg/DE)
- P56 Age of menarche and clinical features of migraine
E. Kiryanova, G. Tabeeva (Moscow/RU)
- P57 Different impacts of migraine-associated features on disability and psychiatric comorbidities in patients with migraine without aura
N. Imai (Shizuoka/JP), Y. Matsumori (Sendai/JP)
- P58 Functional approach to headaches and migraines
A. Lurye (Almaty/KZ)
- P59 Neuro - psychological analysis of patients with severe types of migrain in Uzbekistan region
D. Akmaljonova, A. Sabirova, B. Rahimov (Tashkent/UZ)
- P60 ANALYSIS REPORT OF PSYCHO-EMOTIONAL CONDITION IN 32 PATIENTS WITH PRIMARY HEADACHE IN UZBEKISTAN
A. Sabirova, D. Akmaljonova, M. Ergasheva, B. Rahimov (Tashkent/UZ)
- P61 Is Headache control overemphasized? An innovative behavior headache therapy for primary headaches: a randomized controlled trial of efficacy
V. Vasilio (Cork/IE), E. Karademias (Rethymnon/GR), S. Papacostas, Y. Christou, M. Karekla (Nicosia/CY)
- P62 Long-term improvement in migraine outcomes following participation in an employer-provided disease management program
L. Schaeetz, T. Rimner (Basel/CH), P. Pathak (Dublin/IE), J. Fang (East Hanover/US), D. Chandrasekhar, L. Vandervoort (Singapore/SG), J. Mueller (Basel/CH), P. S. Sandor, A. R. Gantenbein (Zurich/CH)
- P63 The Socioeconomic Burden of Migraine: An Evaluation of Productivity Losses due to Migraine-Headaches Based on a Population Study in Germany
A. H. Seddik, J. C. Branner (Darmstadt/DE), D. A. Ostwald (Darmstadt, Berlin/DE), Z. Katsarava (Unna, Essen/DE, Tbilisi/GE, Moscow/RU), S. Schramm (Essen/DE), M. Bierbaum (Nuernberg/DE)

- P64 The increasing importance of a dedicated nurse team in headache research
M. Bianchi, L. Gracardi, S. Lunghi, V. Tosca, G. Sances, C. Tassorelli (Pavia/IT)
- P65 Clinical characteristics of patients and healthcare resource utilisation in European centres with and without dedicated headache clinic: Real-world evidence from the multinational BECOME study
P. Pozo-Rosich (Barcelona/ES), D. P. B. Watson (Aberdeen/GB), P. Martelletti (Rome/IT), C. Lucas (Lille/FR), C. Gaul (Königstein im Taunus/DE), S. Ritter (East Hanover/US), J. Snellman (Basel/CH)
- P66 Migraine Diagnosis by Integrating Ceramide Biomarker Concentration Checking and von Willebrand Factor Biomarker Activity (vWF) with Diagnostic Criteria based on the Voremide Algorithm.
R. Fajar (Sleman/ID)
- P67 Osmophobia and migraine-related limitation of everyday activities
M. Frost, A. Hähner, A. Klimova, R. Sabatowski, G. Goßrau (Dresden/DE)
- P68 Natural selection and migraine prevalence
M. Lisicki, E. Marucco, M. Carpinella (Córdoba/AR), M. Manise, A. Maertens de Noordhout (Liège/BE), D. Conci (Córdoba/AR), J. Schoenen (Liège/BE)
- P69 Diagnostic and Therapeutic management of migraine in an Emergency Department: our experience
F. J. Cabello Murgui, M. Payá Montes, C. Nieves Castellanos, S. Díaz Insa (Valencia/ES)
- P70 Migraine comorbidity with anxiety disorder, a study in Regional Hospital Durres, Albania
E. Harizi (Shemsi), F. Domi (Durres/AL), K. Shemsi, E. Shemsi (Tirana/AL)
- P71 Headache Prevalence and Distribution in a Population-Based Study of Older Adults in Albania
I. Alimehmeti, E. Reka, A. Gezhilli, A. Kuqo, J. Kruja (Tirana/AL)
- P72 Migraine prevalence among Russian neurologists
K. Skorobogatykh, J. Azimova (Moscow/RU)
- P73 Characteristics of Headache Education during Residency of Neurology in European Countries. A survey of the EAN-RRFS National Representative Network study
D. García-Azorín (Valladolid/ES), M. van der Meulen (Rotterdam/DE), N. N. Kleineberg (Cologne/DE), V. Carvalho (Matosinhos/PT), V. Kosta (Split/HR), G. di Liberto (Lausanne/CH), L. Klingelhöfer (Dresden/DE), L. Cuffaro (Palermo/IT), P. Irimia (Pamplona/ES), R. H. Jensen (Copenhagen/DK)
- P74 Prevalence of psychological symptoms in migraine teenagers with and without aura
A. Yusupov, B. Nabiyeu, U. Shamsiyeva (Tashkent/UZ)
- P75 Association between Migraine and Other Cochlear Disorders In students: Cross-sectional study.
N. Ibrohimova, Y. Musayeva, F. Qarshiboyev (Tashkent/UZ)
- P76 Evaluation of headache service quality indicators in primary care in Europe
B. Lenz, Z. Katsarava (Unna/DE), R. Gil-Gouveia (Lisbon/PT), G. Karelis (Riga/LV), B. Kaynarkaya (Istanbul/TR), L. Meksa (Riga/LV), E. Oliveira, F. Palavra, I. Rosendo (Coimbra/PT), M. Sahin

(Istanbul/TR), B. Silva (Coimbra/PT), S. Turkmen (Istanbul/TR), I. Varsberga-Apsite (Riga/LV), Y. Ziya (Istanbul/TR), L. Zvaune (Riga/LV), T. J. Steiner (Trondheim/NO)

- P79 Experience of the use of calcitonin gene-related peptide pathway antibodies as migraine preventive therapies in andalusian population. A multicenter study.
R. Lamas Pérez, F. J. Viguera Romero (Sevilla/ES), C. Jurado Cobo (Córdoba/ES), A. Gómez Camello, J. Pelegrina Molina (Granada/ES), M. D. Jiménez Hernández, C. González Oria (Sevilla/ES)
- P80 Rapid referral for headache management from Emergency Department to Headache Centre: four years data
A. Negro, V. Spuntarelli, P. Martelletti (Rome/IT)
- P81 Prevalence, clinical characteristics of headache in medical students at Alzaiem Alazhari university in 2020, Khartoum, Sudan
R. Tofaha Alhousseini, M. Alfatih Abdoalgadir, M. Ibrahim, A. Idriss (Khartoum/SD)
- P82 Evaluating the quality of life of patients with migraine according to the received therapy
Z. Akbarkhodjaeva, F. Saidvaliev (Tashkent/UZ)
- P83 Smart migraine: A platform for headache assistance and clinical research.
R. Lamas Pérez, G. A. Escobar Rodríguez, J. Moreno Conde, M. Millán, L. Muñoz, J. Arriola, R. Pérez Esteban, M. D. Jiménez Hernández, C. González Oria (Sevilla/ES)
- P85 Analysis of the decrease in daily activity in migraine
M. Sanoyeva, M. Gulova, M. Avezova (Bukhara/UZ)

18:55–19:20 Headache and the COVID Pandemic – Headache Treatment during the COVID Pandemic
Chair S. Sacco (L'Aquila/IT)

- 18:55 Headache medication and the COVID-19 pandemic
IL03 A. Maassen van den Brink (Rotterdam/NL)

19:25–20:25 Sponsored Symposium 1 – Industry Sponsored Symposium

- 19:25 Welcome and introduction
U. Reuter (Berlin/DE)
- 19:30 The European “burden of diseases” -Advancing the journey to optimal migraine management
Z. Katsarava (Unna, Essen/DE)
- 19:40 One Europe, one indication, but divers treatment options
S. Evers (Copenbrügge/)
- 19:50 From clinical Data up to own ideas in research
M. Ashina (Copenhagen/DK)
- 20:00 Implementing migraine prophylaxis into the real world – a European perspective
M. Sanchez del Rio (Madrid/ES)
- 20:10 Discussion / Conclusion - What did we learn from the qualifier round?
U. Reuter (Berlin/DE)

20:30–21:00 Teaching Course 1 – Headache Clinics

- Chairs S. Ashina (Brookline/US), M. Sanchez del Rio (Madrid/ES), D. García-Azorín (Valladolid/ES)
- 20:30 Clinical history, red flags, and imaging, with case examples.
D. García-Azorín (Valladolid/ES), M. Sanchez del Rio (Madrid/ES)
- 20:45 Treatment approach
S. Ashina (Brookline/US), M. Sanchez del Rio (Madrid/ES)

21:05–22:00 Evening Program – A Wine Journey

30.06.2020

16:30–17:30 Scientific Session 2 – Cluster Headache and Other Topics

- Chairs M. Ashina (Copenhagen/DK), S. Benemei (Florence/IT)
- 16:30 Update cluster
IL04 G. Lambru (London/GB)
- 16:45 Calcitonin gene-related peptide levels in tear fluid are elevated in cluster headache patients compared to healthy controls
AL06 K. Kamm, R. Ruscheweyh, A. Straube (Munich/DE)
- 16:50 Quantification of facial microvascular blood flow in cluster headache using laser speckle contrast imager: Differences between episodic and chronic cluster headache
AL07 A. P. Andreou, M. Murphy, B. Hill, R. Abuukar Abdullahi, A. Al-Kaisy, G. Lambru (London/GB)
- 16:55 Safety and tolerability of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment
AL08 M. J. A. Láinez (Valencia/ES), J. Schoenen (Liege/BE), C. Stroud, J. Bardos, M. Bangs, P. Kemmer, R. Wenzel, D. Kuruppu, J. M. Martinez, T. M. Oakes (Indianapolis/US)
- 17:00 REFRACTORY CHRONIC MIGRAINE: COULD IT BE IDIOPATHIC INTRACRANIAL HYPERTENSION? DATA FROM A TERTIARY HEADACHE CENTER
AL09 E. Colangeli, R. Ornello, F. Gabriele, C. Scarpato, C. Tiseo, I. Frattale, E. De Matteis, S. Sacco (L'Aquila/IT)
- 17:05 Noninvasive Evaluation of Intracranial Compliance in Spontaneous Intracranial Hypotension: Case series
AL10 M. N. P. Souza, G. Kubota, S. Wayhs, C. Hayashi, G. Vilela, S. Lima, I. Fortini, M. Calderaro (São Paulo/BR)
- 17:10 Critical appraisal of outcome measures in Idiopathic Intracranial Hypertension and surrogate outcomes for Intracranial Pressure
AL11 V. Vijay, J. Mitchell, E. Bilton, A. Yiangou, Z. Alimajstorovic, O. Grech, K. Brock, P. Nightingale, S. Mollan, A. Sinclair (Birmingham/GB)
- 17:15 Provocation studies in Cluster headache
IL05 A. L. Vollesen (Glostrup, Copenhagen/DK)

17:00–18:00 Sitzung 1 – Headache Days

- 17:15 Migräne – Wo liegen die Stolperstellen?
R. Ruscheweyh (München/DE)
- 17:30 Gesichtsschmerzen: Ist es immer der Trigeminus?
T. P. Jürgens (Rostock/DE)
- 17:45 Live-Diskussion

17:35–17:50 Poster Session and Break – Poster of the Day

17:35–17:50 Cluster Headache

- P86 Prednisone in Short-term Prevention of Episodic Cluster Headache

M. Obermann (Essen, Seesen/DE), S. Nägel (Halle (Saale)/DE), C. Gaul (Königstein/DE), P. Storch (Jena/DE), A. Böger (Kassel/DE), T. Kraya (Leipzig/DE), J.-P. Jansen (Berlin/DE), A. Straube (Munich/DE), T. Freilinger (Passau/DE), H. Kaube (Munich/DE), T. P. Jürgens (Rostock/DE), H.-C. Diener (Essen/DE), Z. Katsarava (Essen, Unna/DE), D. Holle (Essen/DE)

- P87 Clinical factors influencing the impact of cluster headaches from a prospective multicenter study
S.-J. Cho (Hwaseong/KR), J.-H. Sohn (Chuncheon/KR), J.-W. Park (Uijeongbu/KR), M. J. Lee, P.-W. Chung, M. K. Chu, B.-K. Kim (Seoul/KR)
- P89 Clinical phenotypes and responsiveness to sumatriptan in cluster headache
L. Gianj, A. Proietti Cecchini, A. Astengo, G. Lauria Pinter, M. Leone (Milan/IT)
- P90 Secondary SUNCT syndrome and hyperprolactinemia: a new case
T. Makeeva (Voronezh/RU), D. Khutorov, M. Koreshkina (St. Petersburg/RU)
- P91 The effect of pituitary adenylate cyclase-activating peptide-38 and vasoactive intestinal peptide in cluster headache
A. L. Vollesen, A. Snoer, B. A. Chaudhry, A. S. Pedersen, A. Hagedorn Jespersen (Glostrup/DK), J. Hoffmann (London/GB), R. Højland Jensen, M. Ashina (Glostrup/DK)
- P93 Great occipital nerve steroid injections in cluster headache.
E. Merli, G. M. Asioli, V. Favoni, G. Giannini, D. Mascarella, S. Cevoli, G. Pierangeli (Bologna/IT)
- P94 High-dose intravenous methylprednisolone for treatment of cluster headache.
F. Ursitti, L. Papetti, M. A. N. Ferilli, G. Sforza, R. Moavero, M. Valeriani (Rome/IT)
- P95 Characteristics of pre-cluster symptoms in cluster headache: a cross-sectional multicenter study
S. Cho (Seoul/KR), S.-J. Cho (Hwaseong/KR), J.-Y. Ahn, M. K. Chu, J. M. Chung, P.-W. Chung (Seoul/KR), B.-S. Kim (Seongnam/KR), D. Kim, J.-M. Kim (Daejeon/KR), M. J. Lee, H.-S. Moon, K. Oh (Seoul/KR), J.-W. Park (Uijeongbu/KR), J.-H. Sohn (Chuncheon/KR), C.-S. Chung, B.-K. Kim (Seoul/KR)
- P96 PULSED RADIOFREQUENCY ON OCCIPITAL NERVES IN CLUSTER HEADACHE: A CASE SERIES
 Belgrado E¹, Gigli GL², Valente M², ¹ Neurology Department University Hospital Santa Maria Misericordia Udine Italy ² Neurologic Clinic University of Udine Hospital Santa Maria Misericordia Udine Italy
M. Valente, E. Belgrado, G. L. Gigli (Udine/IT)
- P97 Analysis of variants in NOS genes in relation to Cluster headache and predisposing factors
C. Ran, C. Fourier, J. M. Michalska, C. Sjöstrand, E. Waldenlind, A. Steinberg, A. Carmine Belin (Stockholm/SE)
- P98 Secondary SUNCT Syndrome: Literature Review
D. Khutorov (St. Petersburg/RU), T. Makeeva (Voronezh/RU), D. Korobkova (Moscow/RU)
- P100 Acute treatment is more effective in patients with episodic compared with chronic cluster headache - Results from the Danish Cluster Headache Survey
A. S. Petersen, N. Lund, R. H. Jensen, A. S. Pedersen, M. Barloese (Glostrup/DK)
- P101 The clinical profile of cluster headache in Iranian patients in southern region of Iran
A. Ghabeli Juibary (Marvdasht/IR)

- P111 THE NEED FOR OTOSCOPY BEFORE INVASIVE OR NEUROIMAGING MODALITIES IN THE WORK-UP OF INDETERMINATE HEADACHES IN CHILDREN
O. Komolafe, A. Adebawale, A. Adeyemo, M. Asaleye, I. Ogunbameru (Ile-Ife/NG)
- P112 TYPE OF HEADACHE AT ONSET AND SEVERITY OF REVERSIBLE CEREBRAL VASOCONSTRICTION SYNDROME.
K. Lange (Montpellier/FR), C. Burcin, J. Mawet, C. Roos (Paris/FR), A. Ducros (Montpellier/FR)
- P113 The association between headaches and temporomandibular disorders is confounded by bruxism and somatic complaints: a retrospective medical file study.
H. van der Meer (Amsterdam, Nijmegen, Utrecht/NL), C. Speksnijder (Utrecht/NL), R. Engelbert, F. Lobbezoo (Amsterdam/NL), M. Nijhuis - van der Sanden (Nijmegen/NL), C. Visscher (Amsterdam/NL)
- P114 Cerebral lesion correlates of trigeminal neuralgia in multiple sclerosis
K. Fröhlich (Erlangen/DE), R. Linker, D.-H. Lee (Regensburg/DE), T. Engelhorn, A. Dörfler, F. Seifert, S. Schwab, K. Winder (Erlangen/DE)
- P116 Headache and cerebral hemodynamics in children with consequences of transferred meningoencephalitis
N. Maxamatjanova, G. Ishankhodjayeva (Tashkent/UZ)
- P117 Postdural puncture headache, but not lumbar puncture itself, leads to the clinical worsening of previous chronic headache. One year follow up study.
S. Ljubisavljevic (Nis/RS), J. Zidverc Trajkovic (Belgrade/RS), M. Ljubisavljevic (Nis/RS)
- P118 Erenumab for Post-Meningitic Headache
K. Arca, M. Grill, R. Halker Singh (Scottsdale/US)
- P119 Headache phenotype in idiopathic intracranial hypertension is predominantly migraine-like: Characteristics from the Idiopathic Intracranial Hypertension Weight Trial (IIH:WT)
B. Wakerley (Gloucester/GB), J. Mitchell, R. Ottridge, A. Yiangou, Z. Alimajstorovic, V. Vijay, T. Matthews (Birmingham/GB), A. Ansons (Manchester/GB), S. Hickman (Sheffield/GB), J. Benzimra (Exeter/GB), M. Lawden (Leicester/GB), B. Davies (Stoke/GB), O. Grech, N. Ives, S. Patel, R. Woolley (Birmingham/GB), C. Rick (Nottingham/GB), R. Singhal, A. Tahrani, S. Mollan, A. Sinclair (Birmingham/GB)
- P120 Cardiac cephalgia: an uncommon headache to be aware of!
A. F. Jorge, P. Faustino, A. C. Lima, F. Moreira, I. Luzeiro (Coimbra/PT)
- P121 Clinical characteristics of idiopathic cerebrospinal fluid leak developed with thunderclap headache: for an early diagnosis
Y. Nakazato, K. Ikeda, K. Ota, M. Takashi, K. Kawasaki, T. Fukuoka (Saitama/JP), A. Tanaka (Tottori/JP), N. Tamura, T. Yamamoto (Saitama/JP)
- P122 Describing the impact of headache in the words of people with Idiopathic Intracranial Hypertension – A qualitative social media study.
A. Denton, S. Williamson (Exeter/GB), O. Grech, S. Mollan, A. Sinclair (Birmingham/GB)
- P123 Efficacy of Trigger Points Massage in Severity of Chronic Tension Headache: An Unmasked, Randomized, Controlled Trial
A. Sharifi-Razavi, E. Sharifi-Razavi, M. Tabarestani (Sari/IR)

- P124 Investigation of Eating Disorder and Psychiatric Comorbidity in Idiopathic Intracranial Hypertension
Ç. Ulukan, U. Çıkrıkçılı, M. Sezgin, E. Berberoğlu, E. Ekizoğlu Turgut, E. Kocasoy Orhan, B. Yücel, B. Baykan (Istanbul/TR)
- P125 New daily persistent headache: a systematic review on an enigmatic disorder
N. Yamani (Tehran/IR), J. Olesen (Copenhagen/DK)
- P126 Features of New daily persistent headache in a pediatric cohort.
L. Papetti, G. Sforza, S. Tarantino, F. Ursitti, M. A. N. Ferilli, R. Moavero, M. Valeriani (Rome/IT)
- P127 Proton nuclear magnetic resonance spectroscopy-based metabolomic analysis has diagnostic potential in Idiopathic Intracranial Hypertension and sheds light on disease processes
S. Y. Seneviratne, Z. Alimajstorovic, A. Yiangou, J. Mitchell, V. Vijay, O. Grech, S. Mollan, C. Ludwig, A. Sinclair (Birmingham/GB)
- P128 Primary stabbing headache in children and adolescents: is it a "migraine precursor"?
M. Valeriani, F. Ursitti, M. A. N. Ferilli, R. Moavero, S. Tarantino, G. Sforza, C. Ruscitto, F. Vigevano, L. Papetti (Rome/IT)
- P129 Management of Trigeminal Neuralgia during pregnancy and breastfeeding: Results from a survey including 106 Spanish Neurologists.
A. Mínguez-Olaondo (Navarra, Donostia-San Sebastián/ES), D. García-Azorín (Valladolid/ES), N. Morollón Sánchez-Mateos (Barcelona/ES), A. Gago-Veiga (Madrid/ES), M. Torres-Ferrús (Barcelona/ES), P. Irimia (Navarra/ES), Á. L. Guerrero Peral (Valladolid/ES), S. Santos-Lasaosa (Zaragoza/ES)
- P130 Clinical characterization of Epicrania Fugax: a case series
A. Jaimes Sánchez, J. L. Hernández Alfonso, J. Rodríguez Vico (Madrid/ES)
- P131 Intracranial hypertension and systemic lupus erythematosus
D. Turki, S. Sakka, S. Sallem, S. Daoud, N. Farhat, M. Damak, C. Mhiri (Sfax/TN)
- P132 The systemic and CNS metabolite profile in IIH using untargeted mass spectrometry analysis.
Z. Alimajstorovic, J. Mitchell, A. Yiangou, L. Najdekr, A. Jankevics, G. Lloyd, V. Vijay, O. Grech, R. Ottridge, S. Mollan, W. Dunn, A. Sinclair (Birmingham/GB)
- P133 Persistent idiopathic facial pain: Guidelines to the general practitioners
L. Melek (Alexandria/EG)
- P134 BOTULINUM NEUROTOXIN (BoNT) INJECTION FOR REFRACTORY TRIGEMINAL NEURALGIA: A CASE SERIES FROM A SINGLE CENTER. Valente M, Lettieri C, Gigli GL Department of Neurosciences, University Hospital, Udine, Italy
M. Valente, C. Lettieri, G. L. Gigli (Udine/IT)
- P135 Results from a pilot randomized controlled trial of a community-based mindfulness-based stress reduction intervention versus usual care for moderate-to-severe migraine headache
A. Pressman, A. Jacobson, H. Law (Walnut Creek/US), R. Stahl (Santa Cruz/US), A. Scott, M. Goodreau, S. Sudat (Walnut Creek/US), A. Avins (Oakland/US)
- P136 Rates and predictors of relapse in medication overuse headache: a clinic-based study from China.
D. Zhao (Beijing/CN)

- P137 Experience with botulinum toxin in the treatment of chronic post-traumatic headache
B. Böhringer (Murnau/DE)
- P138 Headache and HIV in sub-Saharan Africa: a cross sectional study at the DREAM Centre, Malawi
M. Leone, L. Giani (Milan/IT), M. Mwazangati (Blantyre/MW), D. Uluduz (Istanbul/TR), T. Şaşmaz (Mersin/TR), M. Kamponda, V. Tolno (Blantyre/MW), G. Guidotti, M. C. Marazzi (Rome/IT), T. J. Steiner (London/GB)
- P139 Headache due to intracranial hypertension secondary to sleep apnea in hyperostosis
L. Rapisarda, G. Demonte, C. Bombardieri, F. Rocchia, M. Gagliardi, G. Annesi, R. Procopio, A. Gambardella, F. Bono (Catanzaro/IT)
- P142 Harlequin syndrome as a rare complication of cervical artery dissection
L. Kalashnikova, M. Gubanova, A. Belopasova, L. Dobrylina (Moscow/RU)
- P143 Headache, but not obesity, is a risk factor for hypertension caused by obstructive sleep apnea
S. Khamsai, K. Sawanyawisuth (Khonkaen/TH)
- P144 Headaches during pregnancy: Management Protocols within the Emergency Department
M. Payá Montes, S. Díaz Insa, C. Nieves Castellanos, F. J. Cabello Murgui (Valencia/ES)
- P145 Sentinel headache before transient ischemic attacks and ischemic stroke
E. R. Lebedeva, A. V. Ushenin, N. M. Gurary, D. V. Gilev (Yekaterinburg/RU), J. Olesen (Copenhagen/DK)
- P146 Dialysis – induced headache
P. Djamandi, L. Shehaj, H. Gorica, N. Mitrollari, M. Rroji, J. Kruja (Tirana/AL)
- P147 Headache and the sporadic form of meningioangiomas
P. Řehulka, M. Hermanová, M. Brázdil (Brno/CZ)
- P148 Characterization of persistent headache attributed to past stroke
A. Rêgo, F. Bernardo, R. Pinheiro, S. Delgado, E. Parreira (Lisbon/PT)
- P149 The Idiopathic Intracranial Hypertension Weight Trial (IIH:WT) baseline characteristics: a multicentre, randomised controlled trial assessing bariatric surgery versus a community weight loss programme
S. Mollan, J. Mitchell, R. Ottridge, A. Yiangou, V. Vijay, Z. Alimajstorovic, R. Woolley, S. Patel, N. Ives, T. Matthews (Birmingham/GB), B. Wakerley (Gloucester/GB), A. Ansons (Manchester/GB), S. Hickman (Sheffield/GB), J. Benzimra (Exeter/GB), M. Lawden (Leicester/GB), B. Davies (Stoke-on-Trent/GB), C. Rick (Nottingham/GB), R. Singhal, A. Tahrani, A. Sinclair (Birmingham/GB)
- P150 FACIAL EPICRANIA FUGAX SECONDARY TO AN ANEURISM IN INTERNAL CAROTID ARTERY: A NEW SYMPTOMATIC CASE
M. Gutierrez Sanchez, J. Galvan, M. Schuller, M. Galdamez, Á. Sierra-Mencía, Á. L. Guerrero Peral, D. García-Azorín (Valladolid/ES)
- P151 PREVALENCE OF HEADACHES IN PATIENTS WITH EPILEPSY IN UZBEKISTAN
D. Daminov (Tashkent/UZ)
- P152 Usefulness of Transcranial Color Doppler in the diagnosis of Reversible Cerebral Vasoconstriction Syndrome

R. Oliveira, P. Batista, N. Inacio, R. Gil-Gouveia (Lisbon/PT)

P153 Headache following cerebrovascular events and correlation of cardiovascular biomarkers/ risk factors with primary and secondary headache disorders
K. Kaltseis, L. Domig, S. Komarek, F. Frank, M. Knoflach, G. Brössner (Innsbruck/AT)

P154 Pericranial nerve block in patients with headache difficult to treat: an option in a emergent country.
R. Dominguez-Moreno, F. A. Vega-Boada (Mexico City/MX)

P155 Neurological manifestations as the best predictor of abnormalities in tomography in Mexican patients attended by emergency headache
R. Garcia, J. Hernandez, R. Carrera (Mexico City/MX)

P156 Presence of Headache in Multiple Sclerosis Patients receiving B-cell depleting therapies compared to placebo: A Systematical Review Approach.
T. Mavridis, N. Papagiannakis, M. Breza, A. Laskaratos, D.-D. Mitsikostas (Athens/GR)

19:30–20:00 EHF Lecture – Neuromodulation

Chair P. Pozo-Rosich (Barcelona/ES)

19:30 Neuromodulation

IL06 M. Lisicki (Cordoba/ES)

20:05–21:05 Sponsored Symposium 3 – Real World Migraine - Approaches for Best Practice

20:05 Welcome an Introduction
H.-C. Diener (Essen/DE)

20:08 Management of Patients With Difficult-to-treat Migraine
H.-C. Diener (Essen/DE)

20:23 Management of Patients With Migraine and Comorbidities
M. J. A. Láinez (Valencia/ES)

20:38 Management of Patients With Migraine and Cardiovascular Risk Factors
C. Lampl (Linz/AT)

20:53 Panel Discussion and Close
H.-C. Diener (Essen/DE)

21:10–22:00 Evening Program – A Tour through Berlin

01.07.2020

16:30–17:30 Scientific Session 3 – Basic Research

- Chairs A. Maassen van den Brink, E. Rubio-Beltrán (Rotterdam/NL)
- 16:30 CGRP receptor biology
IL07 D. L. Hay (Auckland/NZ)
- 16:45 Two-Hour Infusion of Vasoactive Intestinal Polypeptide Promotes Delayed Headache and Extracranial Vasodilation in Healthy Participants
AL12 L. Pellesj, M. Al-Mahdi Al-Karagholi, B. A. Chaudhry, F. M. Amin, M. Ashina (Copenhagen/DK)
- 16:50 Adrenomedullin induces migraine-like attacks in patients with migraine without aura
AL13 H. Ghanizada, M. Al-Mahdi Al-Karagholi, N. Arnggrim, M. Mørch-Rasmussen (Glostrup/DK), C. S. Walker, D. L. Hay (Auckland/NZ), M. Ashina (Glostrup/DK)
- 16:55 Investigation of mitochondrial respiratory function in a brain slice model of cortical spreading depression.
AL14 O. Grech, D. Fulton, Z. Alimajstorovic, S. Heising, D. Cartwright (Birmingham/GB), G. C. Faas, A. C. Charles (Los Angeles/US), A. Sinclair, G. G. Lavery (Birmingham/GB)
- 17:00 Resting State Functional Connectivity Changes of the Hypothalamus in Migraine Patients: A Cross-Sectional and Longitudinal Study
AL15 R. Messina, M. A. Rocca, P. Valsasina, P. Misci, M. Filippi (Milan/IT)
- 17:05 Gene expression in the cortical region that harbours V3a and its possible implications with migraine
AL16 M. Lisicki, M. Carpinella (Córdoba/AR), G. Coppola (Latina/IT), E. Ruiz Romagnoli (Buenos Aires/AR), M. Manise, A. Maertens de Noordhout (Liège/BE), D. Conci (Córdoba/AR), J. Schoenen (Liège/BE)
- 17:10 CGRP and migraine from a cardiovascular point
IL08 M. Guglielmetti (Rome/IT)

17:00–18:00 Sponsored Symposium 4 – ASCOTOP®

- 17:00 Akuttherapie der Migräne mit Triptanen - Bewehrt und unverzichtbar?
C. Gaul (Königstein im Taunus/DE), M. Marziniak (München/DE)

17:40–18:35 Teaching Course – Headache Science

- Chairs A. Sinclair (Birmingham/GB), F. M. Amin (Copenhagen/DK), E. Rubio-Beltrán (Rotterdam/NL)
- 17:40 How to plan a study, how to analyze the data, how to write a paper
A. Sinclair (Birmingham/GB), F. M. Amin (Copenhagen/DK), E. Rubio-Beltrán (Rotterdam/NL)

18:00–19:00 Sitzung 2 – Headache Days

- 18:00 Migräneattacken effektiv behandeln
L. Neeb (Berlin/DE)
- 18:15 Medikamentöse und nicht-medikamentöse Basismaßnahmen in der Migräneprophylaxe
C. Gaul (Königstein im Taunus/DE)
- 18:30 Kopfschmerzen im Alter: Erkennen und behandeln

T. Kraya (Leipzig/DE)

18:45 Live-Diskussion

18:45–19:15 Poster Session and Break – Poster of the Day

Chairs A. Maassen van den Brink (Rotterdam/NL), A. Ducros (Montpellier/FR), F. M. Amin (Copenhagen/DK)

18:45–19:15 Basic Human

P157 Evaluation of anomalies of cerebral vessels in patients without cephalic syndrome
M. Salokhiddinov, F. Umarov (Tashkent/UZ)

P158 α CGRP INDUCED CHANGES IN CEREBRAL AND SYSTEMIC CIRCULATION; A TCD STUDY
D. Visočnik, M. Zaletel, M. Zupan, B. Žvan (Ljubljana/SI)

P159 Is stimulation of the Human cortex able to provoke headache? A stereo-electroencephalography (SEEG) study
G. Demarquay, E. Hotolean, F. Mauguiere, L. Mazzola (Bron/FR)

P160 Sumatriptan does not antagonize CGRP induced symptoms in healthy volunteers
K. Falkenberg, H. Bjerg, N. Yamani, J. Olesen (Glostrup/DK)

P163 Non-invasive vagus nerve stimulation selectively modulates trigeminal pain processing
K.-P. Peng, A. May (Hamburg/DE)

P164 Classification of Eye Condition based on Electroencephalogram Signals using Extreme Learning Machines Algorithm (ELM)
R. Fajar (Sleman/ID)

P165 Functional mapping of the trigeminal branches and the greater occipital nerve in brainstem and midbrain
J. Mehnert (Hamburg/DE), T. Nielsen (Hamburg/DE, Copenhagen/DK), H. Basedau (Hamburg/DE), R. H. Jensen (Copenhagen/DK), A. May (Hamburg/DE)

18:45–19:15 Basic Lab

P167 Transcytosis in primary endothelial cell cultures and a possible relation to the 5-HT_{2B} receptor in connection to migraine pathogenesis
J. Nicke (Bochum/DE)

P168 Detailed expression analysis of 5-hydroxytryptamine and 5-HT_{1B/1D/1F} receptors in the trigeminal system.
J. Edvinsson, K. A. Haanes (Copenhagen/DK), K. Warfvinge (Copenhagen/DK, Lund/SE), M. Sheykhzade (Copenhagen/DK), L. Edvinsson (Copenhagen/DK, Lund/SE)

P169 The role of oxytocin and the oxytocin receptor in the trigeminal system.
K. A. Haanes, K. Warfvinge (Glostrup/DK), D. Krause (Irvine/US), J. Edvinsson (Copenhagen, Glostrup/DK), L. Edvinsson (Lund/SE, Glostrup/DK)

P170 Pituitary adenylate cyclase-activating peptide and calcitonin gene-related peptide in the trigeminovascular system – two separate signalling systems
J. Edvinsson (Glostrup, Copenhagen/DK), A.-S. Grell, K. Warfvinge (Glostrup/DK), M. Sheykhzade (Copenhagen/DK), L. Edvinsson (Glostrup/DK, Lund/SE), K. A. Haanes (Lund/SE)

- P171 Blocking the CGRP receptor: differences across human vascular beds
T. de Vries (Rotterdam/NL), A. van den Bogaardt (Beverwijk/NL), A. H. J. Danser, A. Maassen van den Brink (Rotterdam/NL)
- P172 Estrogen receptors α , β and GPER in the rat trigeminal system; sex difference and co-localization with CGRP.
A. Maddahi, L. Edvinsson, K. Warfvinge (Copenhagen/DK)
- P173 Does inflammatory cytokines involve in migraine pathogenesis?
 F. Martami, S. Razeghi Jahromi, M. Togha, Z. Ghorbani, M. Seifishahpar, A. Saidpour (Tehran/IR)
- P174 Responses of spinal trigeminal neurons to noxious stimulation of paranasal sinuses – a rat model of rhinosinusitis headache
M. Koch, K. Messlinger (Erlangen/DE)
- P175 Antagonism of TRPA1 channels reverts chronic migraine pain in an animal model
C. Demartini, R. Greco, I. Casini, A. M. Zanaboni (Pavia/IT), C. Nativi (Florence/IT), C. Tassorelli (Pavia/IT)
- P176 Vasodilatory effects of CGRP receptor agonists in isolated human coronary and middle meningeal arteries
E. Rivera-Mancilla, E. Rubio-Beltrán, T. de Vries, A. Vincent (Rotterdam/NL), A. van den Bogaardt (Beverwijk/NL), A. H. J. Danser, A. Maassen van den Brink (Rotterdam/NL)
- P302 No central action of CGRP antagonising drugs
S. L. Tangsgaard Christensen, C. Ernstsén, J. Olesen, D. M. Kristensen (Glostrup/DK)
- P162 Von Frey testing revisited – provision of an online algorithm for improved accuracy of 50% thresholds
S. L. Tangsgaard Christensen (Glostrup/DK), R. B. Hansen (Copenhagen/DK), M. A. Storm, J. Olesen (Glostrup/DK), M. Ossipov (Tucson/US), T. F. Hansen (Glostrup/DK), J. Izarzugaza (Copenhagen/DK), F. Porreca (Tucson/US), D. M. Kristensen (Glostrup/DK)

18:45–19:15 Migraine Pathophysiology

- P177 White matter lesions in migraine: news and challenges`
 S. Shaafi (Tabriz/IR)
- P178 Glutamate levels and perfusion in pons during migraine attacks: a 3 tesla MRI study using proton spectroscopy and arterial spin labeling
S. Younis, C. E. Christensen, M. B. Vestergaard, U. Lindberg, D. Tolnai, O. B. Paulson, H. B. W. Larsson, A. Hougaard, M. Ashina (Glostrup/DK)
- P179 Multi-frequency Analysis of Neuromagnetic activity between Open Eyes and Closed Eyes at Resting state of Migraine
 S. Saifuddin (Dubai/AE)
- P180 Effect of Connective Tissue Manipulation in Migraine Headache: A Preliminary Study
N. Yagci, S. Hareket (Denizli/TR)
- P181 Erenumab modulates hypothalamic processing in migraine patients
C. Ziegeler, J. Mehnert, K. Asmussen, A. May (Hamburg/DE)

- P182 Investigation of sumatriptan and ketorolac trometamol in the human experimental model of headache.
H. Ghanizada, M. Al-Mahdi Al-Karagholi, N. Arngrim, M. Mørch-Rasmussen, M. Metcalf-Clausen, H. B. W. Larsson, F. M. Amin, M. Ashina (Glostrup/DK)
- P183 Inter-ictal assay of circulating peripheral neuroinflammatory mediators in migraine patients treated with non-invasive cervical vagus nerve stimulation
I. Lendvai (Frankfurt am Main/DE), T. Kinfe (Erlangen/DE)
- P184 A common ground for pain and affective disorders among migraine patients according to internet network functional connectivity & alterations
K. Markin, A. Trufanov (St. Petersburg/RU)
- P185 Subcutaneous sumatriptan reduces cilostazol induced headache in migraine patients
K. Falkenberg, H. Bjerg, J. Olesen (Glostrup/DK)
- P186 Cervical muscle strength in episodic and chronic migraine: a controlled study.
L. Florencio (Madrid/ES), C. Pinheiro, T. Will-Lemos, M. Rocha, T. Martins, F. Dach (Ribeirão Preto/BR), C. Fernández-de-las-Peñas (Madrid/ES), A. Oliveira, D. Bevilaqua-Grossi (Ribeirão Preto/BR)
- P187 Assessing sensitization of trigeminal-cervical complex in different phases of the migraine cycle and in chronic migraine
S. Di Antonio, M. Castaldo (Aalborg/DK), C. Finocchi (Genova/IT), P. Torelli (Parma/IT), L. Arendt-Nielsen (Aalborg/DK)
- P188 The effects of Vitamin D3 supplementation on TGF- β and IL-17 Serum Levels in migraineurs: Post hoc analysis of a randomized clinical trial
M. Togha, Z. Ghorbani, P. Rafiee, S. Razeghi Jahromi, M. Djalali, M. Mahmoudi (Tehran/IR)
- P189 Opening of ATP sensitive potassium channels causes migraine attacks with aura
M. Al-Mahdi Al-Karagholi, H. Ghanizada, C. Nielsen, A. Hougaard, M. Ashina (Copenhagen/DK)
- P190 Intradural artery dilation during experimentally induced migraine attacks
C. E. Christensen, S. Younis, U. Lindberg (Glostrup/DK), P. de Koning (Leiden/NL), D. Tolnai (Glostrup/DK), O. B. Paulson (Copenhagen/DK), H. B. W. Larsson, F. M. Amin, M. Ashina (Glostrup/DK)
- P191 Increased Neck Muscle Stiffness in Migraine Patients with Ictal Neck Pain: a Shear Wave Elastography Study
J. Hvedstrup, L. T. Kolding, M. Ashina, H. W. Schytz (Glostrup/DK)
- P192 Correlation between sensitization of trigeminal-cervical complex and functionality of deep cervical flexor muscles during the interictal period in patients with episodic migraine.
S. Di Antonio, M. Castaldo (Aalborg/DK), C. Finocchi (Genova/IT), P. Torelli (Parma/IT), L. Arendt-Nielsen (Aalborg/DK)
- P193 Spinal sensitization and circulating levels of endocannabinoid and non-endocannabinoid lipid mediators during experimentally-induced migraine attacks
R. De Icco, R. Greco, C. Demartini, A. M. Zanaboni (Pavia/IT), A. Reggiani, N. Realini (Genova/IT), M. Allena, D. Martinelli, V. Grillo, G. Sances, C. Tassorelli (Pavia/IT)
- P194 Visual feedback to modulate pain perception: what effects in chronic migraine patients?

S. Bottiroli (Pavia/IT), M. Matamala-Gomez (Milan/IT), G. Sances, M. Allena, G. Sandrini, R. De Icco, E. Guaschino, C. Tassorelli (Pavia/IT)

- P195 Role of pro-inflammatory cytokines in the differential diagnosis of Vestibular Migraine, Meniere Disease and Migraine
M. Flook Pereira, E. Martinez, A. Gallego-Martinez (Granada/ES), E. Martin-Sanz (Getafe/ES), M. Rossi-Izquierdo (Lugo/ES), J. C. Amor-Dorado (Ibiza/ES), A. Soto-Varela (Santiago de Compostela/ES), A. I. Martins (Coimbra/PT), A. Batuecas-Caletrio (Salamanca/ES), P. Perez-Carpena (Granada/ES), L. Frejo (New York/US), J. A. Lopez-Escamez (Granada/ES)
- P196 Serum Neurofilament light chain as a potential biomarker for migraine
L. H. Overeem, B. Raffaelli, M. D. Hofacker, I. Hubalek, A. Siebert, M. Steinicke, J. Mecklenburg, I. Laumeier, L. Neeb (Berlin/DE), N. Tenenbaum (East Hanover/US), J. Klatt, J. Kuhle (Basel/CH), U. Reuter (Berlin/DE)
- P197 IS PERIPHERAL NEUROPEPTIDE RELEASE REDUCED IN WOMEN WITH MIGRAINE? PRELIMINARY RESULTS FROM A CROSS-SECTIONAL STUDY IN PATIENTS WITH POLYCYSTIC OVARY SYNDROME
L. Al-Hassany (Rotterdam/NL), B. K. T. Zick (Rotterdam, Leiden/NL), A. H. J. Danser, J. S. Laven (Rotterdam/NL), M. J. H. Wermer, G. M. Terwindt (Leiden/NL), A. Maassen van den Brink (Rotterdam/NL)
- P198 Calcitonin Gene-Related Peptide (CGRP) plasma levels in patients with migraine and endometriosis
B. Raffaelli, L. H. Overeem, J. Mecklenburg, M. D. Hofacker, C. P. Nowak, L. Neeb, S. Mechsner, U. Reuter (Berlin/DE)
- P199 *CLOCK* gene and migraine: the role of stress
D. Baksa, X. Gonda, N. Eszlari, P. Petschner, G. Bagdy, G. Juhasz (Budapest/HU)
- P200 Pressure Pain Threshold in the trigeminocervical complex muscles in chronic migraine: preliminary data of a cross-sectional observational study
M. Deodato, P. Manganotti, L. D'Accunto, A. Granato (Trieste/IT)
- P202 Association of *CLOCK* rs1801260 polymorphisms in patients with chronic migraine and sleep disorder
H. Genc (Van/TR), A. Ozge, G. Orekici Temel, I. O. Barlas, N. Oksuz (Mersin/TR)
- P203 Distinctive association of single nucleotide polymorphism 1911A>G in the TRPV1 receptor gene with episodic and chronic migraine: the absence of GG genotype as possible biomarker of migraine chronification risk
A. Yakubova, Y. Davidyuk (Kazan/RU), R. Giniatullin (Kazan/RU, Kuopio/FI), A. Rizvanov (Kazan/RU)
- P204 Analysis of genetic variants in *SCN1A*, *SCN2A*, *KCNK18*, *TRPA1* and *STX1A* in migraine
M. Kowalska, M. Predecki, M. Kapelusiak-Pielok, T. Grzelak, U. Łagan-Jędrzejczyk (Poznan/PL), M. Wiszniewska (Piła/PL), W. Kozubski, J. Dorszewska (Poznan/PL)
- P205 Alterations in the upper trapezius muscle in migraine patients assessed by quantitative magnetic resonance imaging using T2 mapping.
M. V. Bonfert, P. Schandelmaier, D. Weidlich, D. Karampinos, C. Börner, G. Urban, H. Koenig, M. N. Landgraf, T. Baum, F. Heinen, N. Sollmann (Munich/DE)
- P206 Contribution of right-to-left shunt to migraine features

I. Frattale, R. Ornello, V. Caponnetto, F. Pistoia, P. Cerrone, C. Tiseo, A. Splendiani, S. Sacco (L'Aquila/IT)

P207 *GENETICALLY MEDIATED RISK FACTORS FOR MIGRAINE WITH AURA*
I. Maryenko (Minsk/BY)

P208 Micro-array analysis of the hypothalamus in the nitro-glycerine animal model of migraine – Investigating the migraine premonitory phase
R. Abuukar Abdullahi, D. Chambers, G. Williams, T. Takahashi, B. Okine, A. Al-Kaisy, G. Lambru, A. P. Andreou (London/GB)

P209 THALAMO-CORTICAL NETWORKS IN MIGRAINE: A PILOT STUDY USING ADVANCED fMRI TECHNIQUES IN EXPERIMENTALLY-INDUCED ATTACKS
D. Martinelli, G. Castellazzi, R. De Icco, A. Bacila, F. Palesi, G. Salvini, M. Allena, E. Guaschino, G. Sances, A. Pichiecchio (Pavia/IT), C. A. M. Gandini Wheeler-Kingshott (London/GB, Pavia/IT), C. Tassorelli (Pavia/IT)

19:20–19:50 New targets for migraine treatment – EHF Invited Lecture: New Targets in Migraine Treatment

Chairs A. Ducros (Montpellier/FR), C. Lampl (Linz/AT)

19:20 New targets

IL09 M. Ashina (Copenhagen/DK)

20:00–21:00 Sponsored Symposium 5 – Chronic Migraine: continuous innovation with BOTOX® (botulinum toxin type A)

20:00 New perspectives on the impact of BOTOX®
R. B. Lipton (Bronx/US)

20:20 Leading the way in real-world evidence: the first decade of data

20:40 From injection to response
P. Pozo-Rosich (Barcelona/ES)

21:05–22:15 Evening Program – Time to Dance

02.07.2020

16:30–17:30 Scientific Session 4 – Migraine

Chairs R. Burstein (Boston/US), M. Togha (Teheran/IR)

16:30 The differential role of mu and delta opioid receptors in headache
IL10 A. Pradhan (Chicago/US)

16:45 Migraine with brainstem aura: defining the core syndrome
AL17 N. Yamani (Tehran/IR), J. Olesen (Copenhagen/DK)

16:50 Acute Treatment Optimization Influences Disability and Quality of Life in Migraine: Results of
the ObserVational Survey of the Epidemiology, tReatment and Care Of MigrainE (OVERCOME)
Study

AL18 D. C. Buse (Bronx/US), A. Kovacik, R. Nicholson, E. Doty, A. Araujo (Indianapolis/US), S. Ashina
(Boston/US), M. L. Reed (Chapel Hill/US), R. E. Shapiro (Burlington/US), Y. Kim
(Indianapolis/US), R. B. Lipton (Bronx/US)

16:55 Offset analgesia - somatotopic endogenous pain modulation in migraine
AL19 T. Sziliszay (Hamburg, Lübeck/DE), W. Adamczyk (Katowice/PL, Lübeck/DE), G. Carvalho (São
Paulo/BR, Hamburg/DE), A. May (Hamburg/DE), K. Lütke (Hamburg, Lübeck/DE)

17:00 Systematic review and meta-analysis on the use of opioids in the acute treatment of migraine
AL20 D. García-Azorín (Valladolid/ES), S. Benemei (Florence/IT), A. Negro (Rome/IT), Á. L. Guerrero
Peral (Valladolid/ES), S. Ashina (Boston/US), P. Martelletti (Rome/IT)

17:05 The Disease Burden of Episodic and Chronic Migraine in France, Spain and the United Kingdom
AL21 S. Díaz Insa (Valencia/ES), S. Santos-Lasaosa (Zaragoza/ES), H. Benhaddi (Wilrijk/BE), L. Lee (San
Mateo/US), P. J. Goadsby (London/GB)

17:10 Functional connectivity studies in migraine
IL11 W. S. van Hoogstraten (Rotterdam/NL)

17:00–18:00 Sitzung 3 – Headache Days

17:00 Spannungskopfschmerz: Ungefährlich oder der Wolf im Schafspelz?
S. Förderreuther (München/DE)

17:15 Häufige Fragen an den Hausarzt: Akupunktur, Antikörper & Co, Akutmedikamente
M. Marziniak (München/DE)

17:30 Komorbiditäten
A. Gendolla (Essen/DE)

17:45 Live-Diskussion

17:35–18:10 Meet the Experts – Emgality: From Clinical Trial to Clinical Practice

17:35 Emgality: From Clinical Trial to Clinical Practice
U. Reuter (Berlin/DE)

18:15–18:45 EHF Clinical Guidelines – EHF Guidelines on Giant Cell Arteritis

Chairs S. Sacco (L'Aquila/IT), A. Sinclair (Birmingham/GB)

18:15 EHF guidelines on giant cell arteritis
IL12 S. Mollan (Birmingham/GB)

18:50–19:20 Poster Session and Break – Poster of the Day

Chairs D.-D. Mitsikostas (Athens/GR), N. Vandebussche (Gent/BE)

18:50–19:20 Migraine

- P211 Multidisciplinary expert consensus for vestibular migraine
X. Qi (Beijing/CN)
- P212 The Migraine Landscape on YouTube: An Analysis of YouTube as a Source of Information on Migraine
H. Saffi, T. P. Do, J. M. Hansen (Glostrup/DK), D. W. Dodick (Scottsdale/US), M. Ashina (Glostrup/DK)
- P213 Googling migraine: A study of Google as an information resource of migraine management
R. Bojazar, T. P. Do, J. M. Hansen (Glostrup/DK), D. W. Dodick (Scottsdale/US), M. Ashina (Glostrup/DK)
- P214 Translation and validation of a German ID Migraine™ version as migraine screening tool
A. Thiele, S. Strauß, A. Angermaier, R. Fleischmann (Greifswald/DE)
- P215 Working and economic impact of migraine in a hospital workplace cohort
E. Caronna, V. J. Gallardo, A. Alpuente, M. Torres-Ferrús, P. Pozo-Rosich (Barcelona/ES)
- P216 A longitudinal study assessing the natural course of Visual Snow Syndrome
M. Graber, A. Scutelnic (Bern/CH), P. J. Goadsby (London/GB), C. Schankin (Bern/CH)
- P217 Migraine with and without aura and coronary artery calcification -Results of the Heinz Nixdorf Recall Study-
S. Schramm, D. Myszkowski, K.-H. Jöckel, R. Erbel, B. Schmidt, N. Lehmann (Essen/DE), Z. Katsarava (Tbilisi/GE, Moscow/RU, Unna/DE), S. Moebus (Essen/DE)
- P218 Is migraine with and without aura a risk factor for stroke? -Sex-specific results of the longitudinal population-based Heinz Nixdorf Recall Study-
S. Schramm, C. E. Wagner, K.-H. Jöckel (Essen/DE), Z. Katsarava (Unna/DE, Tbilisi/GE, Moscow/RU), S. Moebus (Essen/DE)
- P219 The association between serum vitamin D level and migraine headache: a case-control study
F. Eren, A. Demir (Konya/TR)
- P220 Ex-Migraine: Clinical and neurophysiological analysis
V. Osipova, A. Sergeev, G. Tabeeva, E. Snopkova (Moscow/RU)
- P221 Sporadic Hemiplegic Migraine: A case report
S. Shaafi (Tabriz/IR)
- P222 The Stereotypical Image of a Person with Migraine According to Mass Media
K. Gvantseledze (Tbilisi/GE), T. P. Do, J. M. Hansen (Glostrup/DK), R. E. Shapiro (Vermont/US), M. Ashina (Glostrup/DK)
- P223 Body weigh, psychological factors and migraine severity in children and adolescents

S. Tarantino, L. Papetti, A. Di Stefano, V. Messina, F. Ursitti, M. A. N. Ferilli, G. Sforza, R. Moavero, F. Vigevano, S. Gentile (Rome/IT), M. Valeriani (Aalborg, Rome/IT)

- P224 Healthcare Resource Utilization and Economic Burden of Migraine in the United Kingdom, France, and Spain: Results of a Real-world Study
P. Irimia (Pamplona/ES), H. Benhaddi (Wilrijk/BE), F. Morand, F. Maurel (Courbevoie/FR), M. Lanteri-Minet (Nice/FR), P. J. Goadsby (London/GB)
- P225 WEATHER IMPACT ON MIGRAINE IN LATVIA
L. Smeltere, A. Petrinina, R. Ertis (Riga/LV)
- P226 Typical aura without headache with atypical differential diagnosis
E. Kiryanova, G. Tabeeva (Moscow/RU)
- P227 Features of menstrual association of migraine
E. Kiryanova, G. Tabeeva (Moscow/RU)
- P228 Visual Snow Syndrome: Quantification of symptoms over time
M. Graber, A. Scutelnic (Bern/CH), P. J. Goadsby (London/GB), C. Schankin (Bern/CH)
- P229 The impact of migraine on patients' quality of life
P. Ferreira, A. F. Jorge, M. Lopes, B. Silva, I. Luzeiro (Coimbra/PT)
- P230 Unmet needs in Migraine Prevention: An Indian perspective
S. Thakur (Mumbai/IN)
- P231 Neck pain disability is related to the frequency of migraine attacks and the presence of aura
C. Ferreira Pinheiro (Ribeirão Preto/BR), L. Lima Florencio (Madrid/ES), A. Siriani de Oliveira, J. Pradela, M. Rodrigues Rocha, J. Carolina Silva Marçal (Ribeirão Preto/BR), C. Fernández-de-las-Peñas (Madrid/ES), F. Dach, D. Bevilaqua-Grossi (Ribeirão Preto/BR)
- P233 Body Mass Index and its Association with Characteristics of Migraine
K. Abdurakhmonova, G. Rakhimbaeva (Tashkent/UZ)
- P234 Migraine activity strongly associated with myofascial pain, posture and Flammer syndrome
R. Bubnov (Kyiv/UA), O. Golubnitschaja (Bonn/DE)
- P235 Identifying Differences in the Characteristics of Paediatric Migraine between Male and Female Children
H. Pai (London/GB)

18:50–19:20 Migraine Treatment

- P236 High-velocity low-amplitude chiropractic intervention on a cervical area combined to pharmaceutical treatment for adults with chronic refractory migraine: double-blinded randomized controlled trial
T. Voloshyn, V. Kozyavkin, L. Shestopalova (Truskavets/UA)
- P237 Galcanezumab in migraine prevention: a systematic review and meta-analysis of randomized controlled trials
P. Gklinos, D.-D. Mitsikostas (Athens/GR)
- P238 TREATMENT RESPONSE TO ERENUMAB IN REFRACTORY MIGRAINE PATIENTS
R. Messina, I. Cetta, S. Guerrieri, B. Colombo, M. Filippi (Milan/IT)

- P239 Acute Treatment of Migraine with Fixed Combination of Decarboxylated THC-CBD versus Decarboxylated THC-CBC, Minor Cannabinoids and Terpenes– Pilot data
M. Nicolodj, M. S. Pinnaro (Florence/IT)
- P240 Anticonvulsants as a prevention therapy in pediatric patients with migraine
I. Zaitcey, S. Likhachev, S. Kulikova, S. Belaya, O. Gleb, M. Savchenko, R. Popko (Minsk/BY)
- P241 Improvement in function after lasmiditan treatment: Post-hoc analysis of pooled data from Phase 3 studies
T. Smith (St. Petersburg/US), A. Hake, E. Nery, S. Rathmann, B. Matthews, S. Dowsett, E. Doty (Indianapolis/US)
- P242 Eptinezumab demonstrated migraine preventive efficacy on day 1 after dosing: closed testing analysis from PROMISE-1 and PROMISE-2
D. W. Dodick (Phoenix/US), C. Gottschalk (New Haven/US), S. J. Tepper (Lebanon/US), D. I. Friedman (Dallas/US), R. Cady, J. Smith (Bothell/US), J. Hirman (Woodinville/US), S. Snapinn (Bothell/US)
- P243 Eptinezumab treatment reduced acute headache medication use with corresponding reduction in migraine frequency in patients with chronic migraine and medication-overuse headache in PROMISE-2
H.-C. Diener (Essen/DE), M. J. Marmura (Philadelphia/US), R. P. Cowan (Palo Alto/US), S. J. Tepper (Hanover/US), M. L. Diamond (Chicago/US), A. J. Starling (Phoenix/US), J. Hirman (Woodinville/US), L. Mehta (Bothell/US), T. Brevig, B. Sperling (Copenhagen/DK), E. Brunner (Deerfield/US), R. Cady (Bothell/US)
- P244 Eptinezumab Reduced Acute Medication Use in Patients with Chronic Migraine and Medication-Overuse Headache: Subgroup Analysis of PROMISE-2
M. J. Marmura (Philadelphia/US), H.-C. Diener (Essen/DE), J. Hirman (Woodinville/US), R. Cady (Bothell/US), T. Brevig (Copenhagen/DK), E. Brunner (Deerfield/US), L. Mehta (Bothell/US)
- P245 Eptinezumab Reduced the Frequency of Migraine Days in Patients with Chronic Migraine and Medication-Overuse Headache: Subgroup Analysis of PROMISE-2
H.-C. Diener (Essen/DE), M. J. Marmura (Philadelphia/US), J. Hirman (Woodinville/US), L. Mehta (Bothell/US), T. Brevig (Copenhagen/DK), E. Brunner (Deerfield/US), R. Cady (Bothell/US)
- P246 Eptinezumab Improved Patient-Reported Outcomes in Patients with Chronic Migraine and Medication-Overuse Headache: Subgroup Analysis of PROMISE-2
H.-C. Diener (Essen/DE), M. J. Marmura (Philadelphia/US), R. P. Cowan (Palo Alto/US), M. L. Diamond (Chicago/US), S. J. Tepper (Hanover/US), A. J. Starling (Phoenix/US), J. Hirman (Woodinville/US), L. Mehta (Bothell/US), T. Brevig, B. Sperling (Copenhagen/DK), E. Brunner (Deerfield/US), R. Cady (Bothell/US)
- P247 Relative contribution of early-onset efficacy with eptinezumab to change in headache-related life impact in patients with chronic migraine
R. J. Wirth, J. S. McGinley (Chapel Hill/US), R. B. Lipton (Bronx/US), J. Hirman (Woodinville/US), H. Thomson (Bothell/US), R. Horblyuk (Chapel Hill/US), S. Kymes (Copenhagen/DK), R. Cady (Bothell/US)
- P248 The possibilities of combined using of physical therapy and kinesiotaping for correction of myofascial syndrome in patients with migraine.
M. Mozheiko, I. Maryenko, S. Likhachev (Minsk/BY)

- P249 Pediatric Dose Selection for Fremanezumab (AJOVY) Phase 3 Migraine Studies using Pharmacokinetic Data from a Pediatric Phase 1 Study and a Population Pharmacokinetic Model and Simulation Approach
O. Cohen-Barak (Netanya/IL), A. Radivojevic (East Hanover/US), A. Jones, J. Fiedler-Kelly (Buffalo/US), M. Gillespie, M. Brennan (West Chester/US), D. Gutman (Netanya/IL), M. Rasamoeliso (West Chester/US), P. Loupe (New Orleans/US), L. Rabinovich-Guilatt (Netanya/IL), M. Levi (West Chester/US)
- P250 Galcanezumab in Patients with Treatment-Resistant Migraine: Results from the Open-Label Phase of the CONQUER Phase 3 Trial
H. C. Detke (Indianapolis/US), U. Reuter (Berlin/DE), C. Lucas (Lille/FR), D. Dolezil (Prague/CZ), A. L. Hand (Durham/US), A. Tockhorn-Heidenreich, C. Stroud, S. K. Aurora (Indianapolis/US)
- P251 The effect of high-frequency rhythmic transcranial magnetic stimulation on depression in chronic migraine
V. Hleb, T. Charnukha, S. Likhachev (Minsk/BY)
- P252 Real-world evidence data characterizing the use of the monoclonal antibody Erenumab in daily clinical routine in Germany from the treating physician's perspective
M. Koch (Nuremberg/DE), A. Straube (Munich/DE), P. Stude (Bochum/DE), C. Gaul (Königstein/DE), K. Schuh (Nuremberg/DE)
- P253 First data collection on the use of prophylactic migraine treatments including the monoclonal antibody Erenumab focused on the patient's personal experience
C. Gaul (Königstein/DE), H. Israel-Willner (Berlin/DE), K. Schuh, M. Koch (Nuremberg/DE)
- P254 The effect of zinc supplementation on migraine treatment: a double-blind randomized placebo-controlled clinical trial
F. Khorvash, G. Askari, H. Ahmadi (Isfahan/IR)
- P255 OnabotulinumtoxinA Treatment Improved Health-Related Quality of Life in Adults with Chronic Migraine: Results from a Prospective, Observational Study (PREDICT)
G. Boudreau (Montreal/CA), I. Finkelstein (Toronto/CA), C. Graboski (Brentwood Bay/CA), M. Ong-Lam (Vancouver/CA), S. Christie (Ottawa/CA), K. Sommer (Marlow/GB), M. Bhogal, G. Davidovic (Markham/CA), W. J. Becker (Calgary/CA)
- P256 USING BOTULINUM TOXIN A (DYSPORT) AS A PRINCIPAL APPROACH TO THERAPY OF COMPLICATED FORMS OF MIGRAINE IN UZBEKISTAN
D. Tairova, A. Sabirova, A. Kadirov (Tashkent/UZ)
- P257 Effects of Galcanezumab On Acute Medication Use and Health Care Resource Utilization in Patients With Treatment-Resistant Migraine: Results From a Randomized, Double Blind, Placebo-Controlled Clinical Trial (CONQUER)
A. Ambrosini (Pozzilli/IT), E. Estemalik (Cleveland/US), J. Pascual (Santander/ES), M. Rettiganti, C. Stroud, K. Day, J. H. Ford (Indianapolis/US)
- P258 The effects of a multispecies probiotic supplement on inflammatory markers and episodic and chronic migraine characteristics: A randomized double-blind controlled trial
F. Martami, M. Togha, M. Seifishahpar, Z. Ghorbani, H. Ansari, T. Karimi, S. Razeghi Jahromi (Tehran/IR)
- P259 Effect of a change in lasmiditan dose on drug efficacy and safety: Phase 3 study findings
D. Clemow, H. Hochstetler, S. Rathmann, M. Peres (Indianapolis/US), J. Ailani (Washington/US)

- P260 Coadministration of Single Therapeutic Oral Doses of Atogepant and Sumatriptan Produces No Clinically Relevant Drug-Drug Interactions
R. Boinpally, A. Jakate, M. Butler, A. Periclou (Madison/US)
- P261 Benefits of Long-Term OnabotulinumtoxinA Treatment in Chronic Migraine: Results from the COMPEL Study
A. Blumenfeld (Carlsbad/US), L. Luo (Madison/US), L. Yedigarova (Irvine/US), R. B. Lipton (Bronx/US)
- P262 Sustained Benefits of OnabotulinumtoxinA Treatment in Chronic Migraine: Results from a PREEMPT Pooled Analysis
S. D. Silberstein (Philadelphia/US), H.-C. Diener (Essen/DE), D. W. Dodick (Phoenix/US), L. Luo (Madison/US), L. Yedigarova (Irvine/US), R. B. Lipton (Bronx/US)
- P263 Pregnancy Outcomes Following Exposure to OnabotulinumtoxinA Update – 29 Years of Safety Observation
M. Brin, A. Adams, L. Parker, A. Ukah (Irvine/US), L. Radulian (Bucharest/RO), L. Yedigarova, I. Yushmanova (Irvine/US)
- P264 How and when does the effect of onabotulinumtoxin A wear off over the treatment cycle in chronic migraine? The WEOX study: a retrospective analysis of headache diaries
R. Ruscheweyh (Munich/DE), A. Gryglas-Dworak (Wroclaw/PL), I. Frattale (L'Aquila/IT), L. Nina (Moscow/RU), R. Ornello, S. Sacco (L'Aquila/IT), C. Stark (Heidelberg/AU), M. Torres-Ferrús (Barcelona/ES), B. Athwal (London/GB), P. Pozo-Rosich (Barcelona/ES)
- P265 Vitamin D Supplementation might be effective in migraine prophylaxis probably through attenuating CGRP levels: A randomized double-blind placebo-controlled trial.
Z. Ghorbani, P. Rafiee, A. Fotouhi, S. Haghghi, R. Rasekh Magham, Z. S. Ahmadi, M. Djalali, M. Zareei, S. Razeghi Jahromi, S. Shahemi, M. Mahmoudi, M. Togha (Tehran/IR)
- P266 Healthcare resource use among migraine patients who have failed previous prophylactic treatments: Findings from the BECOME study
P. Martelletti (Rome/IT), C. Lucas (Lille/FR), C. Gaul (Hesse/DE), D. P. B. Watson (Aberdeen/GB), P. Pozo-Rosich (Barcelona/ES), S. Ritter (East Hanover/US), J. Snellman (Basel/CH)
- P267 Ubrogapant is Effective in the Acute Treatment of Migraine with Mild Pain
R. B. Lipton (Bronx/US), D. W. Dodick (Phoenix/US), P. J. Goadsby (London/GB), R. Burstein (Boston/US), A. Adams (Irvine/US), J. Lai, S. Yu, M. Finnegan, J. Trugman (Madison/US)
- P268 The new combination of ibuprofen and caffeine in self-treatment of headache and migraine – Results from a consumer survey in German community pharmacies
H. Gräter, A. Lampert, T. Weiser (Frankfurt am Main/DE)
- P269 Patient satisfaction in randomized controlled trials (RCTs) and pharmacy based (PB) studies investigating ASA, ibuprofen, and the combination ASA, paracetamol and caffeine (APC) for the treatment of acute migraine
H. Gräter, A. Lampert, T. Weiser (Frankfurt am Main/DE)
- P270 Sustained efficacy and safety of erenumab in patients with episodic migraine who failed 2–4 prior preventive treatments: 2-year interim results of the LIBERTY open-label extension study
U. Reuter (Berlin/DE), P. J. Goadsby (London/GB), M. Lanteri-Minet (Nice/FR), T. Stites, S. Wen, N. Tenenbaum (East Hanover/US), M. D. Ferrari (Leiden/NL), S. Pandhi (Basel/CH)

- P271 Effect of erenumab on monthly migraine days and monthly migraine attacks in patients with episodic migraine
P. Tfelt-Hansen, M. Ashina (Glostrup/DK), H.-C. Diener (Essen/DE), S. Ritter (East Hanover/US), G. Paiva Da Silva Lima, S. Rasmussen (Thousand Oaks/US), R. Zielman (Basel/CH)
- P272 Interictal burden of migraine: correlations with other measures of migraine burden and effects of galcanezumab migraine-preventive treatment
R. B. Lipton, D. C. Buse (Bronx/US), C. Sandoe (Toronto/CA), J. H. Ford (Indianapolis/US), A. L. Hand (Durham/US), J. Jedynak, M. Port, H. C. Detke (Indianapolis/US)
- P273 Real-life experience with erenumab in chronic migraine and medication overuse headache in a tertiary Headache Center.
G. Vaghi, G. Fiamingo, R. De Icco, E. Guaschino (Pavia/IT), S. Bottiroli (Pavia, Benevento/IT), V. Bitetto, M. Allena, N. Ghiotto, C. Tassorelli, G. Sances (Pavia/IT)
- P274 Influence of Transcranial Magnetic Stimulation in Management of Migraine Headache
H. Elhabashy, M. Eltamawy, M. Darweesh, A. Elhomran (Cairo/EG)
- P275 Suppression of menstrual related migraine attack severity by pyridoxine, thiamine, and cyanocobalamin: A quasi-experimental within-subject design
M. Togha, R. Rahmanzadeh, S. Nematgorgani, Z. Yari, S. Razeghi Jahromi, F. Refaeian (Tehran/IR)
- P276 An open-label prospective study of the real-world use of Erenumab for the treatment of chronic migraine in patients with idiopathic intracranial hypertension in ocular remission.
A. Yiangou, J. Mitchell, V. Vijay, P. Thomas, C. Fisher, J. Edwards, Z. Alimajstorovic, O. Grech, G. G. Lavery, S. Mollan, A. Sinclair (Birmingham/GB)
- P277 The PEARL Study Protocol: A Pan-European Prospective Observational Study of Fremanezumab Effectiveness in Patients with Chronic or Episodic Migraine in the Real World
M. Ashina (Glostrup/DK), F. M. Amin (Copenhagen, Glostrup/DK), P. Kokturk, J. M. Cohen, M. Konings (Amsterdam/NL), C. Tassorelli (Pavia/IT), D.-D. Mitsikostas (Athens/GR)
- P278 Health-Related Quality of Life Outcomes With Fremanezumab in Patients With Episodic and Chronic Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications: Open-label Extension of the FOCUS Phase 3b Study
L. Mechtler (Buffalo/US), X. Ning, V. Ramirez-Campos, J. M. Cohen, R. Yang (West Chester/US)
- P279 Very Early Onset of Action of Fremanezumab in Patients With Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications: Results of the International, Multicenter, Randomized, Placebo-controlled FOCUS Study
J. Lewis Brandes (Nashville/US), V. Ramirez-Campos, R. Yang, J. M. Cohen (West Chester/US), M. Galic (Amsterdam/NL), X. Ning (West Chester/US), C. Treppendahl (Ridgeland/US)
- P280 Reduction in Migraine Days With Aura with Fremanezumab in Patients With Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications in the Focus Phase 3b Study
M. Ashina (Glostrup/DK), J. M. Cohen, R. Yang, V. Ramirez-Campos, M. Seminerio (West Chester/US), C. Lampl (Linz/AT)
- P281 Efficacy of Fremanezumab by Prior Number of Preventive Treatments With Inadequate Response in Patients With Episodic Migraine and Chronic Migraine: Results of the International, Multicenter Phase 3b FOCUS Study

- L. Pazdera (Rychnov nad Kněžnou/CZ), J. M. Cohen, X. Ning, V. Ramirez–Campos, R. Yang (West Chester/US)
- P282 Patient Satisfaction With Fremanezumab During the Open-label Period of the Phase 3b FOCUS Study in Patients With Episodic and Chronic Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications
L. Mechtler (Buffalo/US), X. Ning, V. Ramirez–Campos, J. M. Cohen, R. Yang (West Chester/US)
- P283 Effect of Fremanezumab on Depression Status in Patients With Episodic and Chronic Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications During the Open-label Period of the Phase 3b FOCUS Study
D. C. Buse (New York/US), J. M. Cohen, V. Ramirez–Campos, R. Yang, X. Ning (West Chester/US), M. Galic (Amsterdam/NL)
- P284 Impact of Fremanezumab on Disability Severity According to the AHS Consensus: Pooled Results of 3 Randomized, Double-blind, Placebo-controlled Phase 3 Studies
A. J. Nagy (Las Vegas/US), J. M. Cohen, X. Ning, V. Ramirez–Campos (West Chester/US), M. Ashina (Glostrup/DK)
- P285 Disability Severity Category Shift with Fremanezumab Treatment: Pooled Results of 3 Randomized, Double-blind, Placebo-controlled Phase 3 Studies
A. J. Nagy (Las Vegas/US), J. M. Cohen, X. Ning, V. Ramirez–Campos, L. Janka (West Chester/US), P. McAllister (Stamford/US)
- P286 Work Productivity and Activity Impairment Outcome With Fremanezumab in Patients With Episodic and Chronic Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications: Open-label Extension of the Phase 3b FOCUS Study
R. B. Lipton (Bronx/US), J. M. Cohen, V. Ramirez–Campos, X. Ning, R. Yang (West Chester/US)
- P287 Efficacy of Fremanezumab in Patients With Episodic and Chronic Migraine And Inadequate Response to 2-4 Classes of Migraine Preventive Medication Due to Lack of Efficacy: Results of the International, Multicenter Phase 3b FOCUS Study
A. J. Nagy (Las Vegas/US), X. Ning, V. Ramirez–Campos, J. M. Cohen, R. Yang, K. Carr (West Chester/US), L. Pazdera (Rychnov nad Kněžnou/CZ)
- P288 May lamotrigine be an alternative to topiramate in the prevention of migraine with aura? Results of a retrospective study
C. L. Smeralda, G. L. Gigli, F. Janes, M. Valente (Udine/IT)
- P289 Efficacy of galcanezumab in patients with high-frequency episodic or chronic migraine and ≥ 3 previous preventive treatment failures: a subgroup analysis from the CONQUER study
M. Weatherall (Aylesbury/GB), M. Matharu (London/GB), A. Pain, A. Tockhorn-Heidenreich, M.-A. Paget, G. Dell'Agnello (Indianapolis/US), G. Lambru (London/GB)
- P290 No additive effect of sumatriptan and olcegepant in a model of migraine
C. Ernstsen, S. L. Tangsgaard Christensen, J. Olesen (Glostrup/DK), D. Møbjerg Kristensen (Glostrup/DK, Rennes/FR)
- P291 TREATMENT WITH TYPE-A BOTULINUM TOXIN IN CHRONIC MIGRAINE IS EFFECTIVE ON PAIN, BUT DOES NOT CHANGE CORTICAL EXCITABILITY AND PLASTICITY Valente M, Russo V, Macorig G, Gentile C, Gigli GL Clinical Neurology, Udine University Hospital, Udine, Italy
M. Valente, V. Russo (Udine/IT), G. Macorig, C. Gentile (Gorizia/IT), G. L. Gigli (Udine/IT)

- P292 Effects of erenumab on sleep and migraine, a clinical and polysomnographic (ERESON) study.
 Valente M, Pellitteri G, Surcinelli A, Pez S, Gigli GL Clinical Neurology, Udine University Hospital, Udine, Italy
M. Valente, G. Pellitteri, A. Surcinelli, S. Pez, G. L. Gigli (Udine/IT)
- P293 Intranasal zucapsaicin for acute treatment of migraine
S. Shokhimardonov (Tashkent/UZ)
- P294 Real world efficacy of candesartan in the treatment of migraine: a retrospective cohort study:
D. García-Azorín, C. Sánchez-Rodríguez, Á. Sierra-Mencía, M. Gutierrez Sanchez, D. Gil Contreras, Á. L. Guerrero Peral (Valladolid/ES)
- P295 Pilot assessment of the effectiveness and tolerability of low-dose combination blood pressure and cholesterol lowering therapy in migraine patients. Randomised double-blind placebo-controlled 3x3 factorial trial (HAPPy pilot).
F. Haghdoost, C. Delcourt, C. Carcel, L. Davies, D. Cordato, A. Zagami, A. Rodgers (Sydney/AU)
- P296 Efficacy and safety of erenumab: real-life data from the Abruzzo region, central Italy
R. Ornello (L'Aquila/IT), A. Casalena (Teramo/IT), I. Frattale (L'Aquila/IT), A. Gabriele (Sulmona/IT), G. Affaitati, M. A. Giamberardino (Chieti/IT), M. Assetta (Teramo/IT), M. Maddestra (Lanciano/IT), S. Viola, F. Marzoli (Vasto/IT), D. Cerone, C. Marini, F. Pistoia, S. Sacco (L'Aquila/IT)
- P297 Erenumab treatment after a stroke like episode in a patient suffering MELAS and migraine - a case report
S. Nägel, P. Burow, S. Zierz (Halle (Saale)/DE), T. Kraya (Halle (Saale), Leipzig/DE)
- P298 THE "TRUE" TROCHLEAR MIGRAINE: THREE CASE REPORTS
E. Correnti, A. D'Amico, M. L. Manzo, L. M. Messina, F. Vanadia, V. Raieli (Palermo/IT)
- P299 Monoclonal Antibody treatment of Migraine in Lisboa – Real life data
R. Gil-Gouveia, I. B. . Marques (Lisbon/PT), A. R. Pinheiro (Amadora/PT), E. Parreira (Lisbon, Amadora/PT), I. Pavão-Martins (Lisbon/PT)
- P300 Dry needling under ultrasound guidance of trigger points in neck and shoulder muscles is effective for treatment tension-type headaches and of migraine attacks
R. Bubnov (Kyiv/UA), L. Kalika (New York/US)
- P301 Real-life data of efficacy and safety of erenumab and galcanezumab in a Headache Unit.

C. Nieves Castellanos (Valencia/ES), M. Olivier (Buenos Aires/AR), L. Monrós Giménez, R. Baviera Muñoz, M. Losada López, S. Díaz Insa (Valencia/ES)

19:25–19:50 EAN / EHF Guidelines

Chairs D.-D. Mitsikostas (Athens/GR), P. Irimia (Pamplona/ES)

19:25 Medication Overuse Headache
H.-C. Diener (Essen/DE)

19:55–20:25 EHF and EFIC – EHF meets EFIC

Chairs C. Lampl (Linz/AT), D. Yarnitzky (Haifa/IL)

19:55 Painful post – Traumatic trigeminal neuropathy
IL13 R. Benoliel (Newark/US)

20:10 Migraine – A neuropathic pain syndrome?
IL14 K. Messlinger (Erlangen/DE)

20:30–21:00 Closing and Award Ceremony

Chairs Z. Katsarava (Unna/DE), Z. Katsarava (Essen/DE), R. B. Lipton (Bronx/US)